BGU Alum Is Evaluating COVID-19 Vaccine
BGU Alum Is Evaluating COVID-19 Vaccine
April 23, 2020
Dr. Colin Fields graduated from BGU’s Medical School for International Health (MSIH) in 2010. Currently he is a sub-investigator on a Phase 1 clinical trial at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle, Washington, evaluating an investigational vaccine for protecting against COVID-19.
Dr. Colin Fields, MSIH ’10
“The COVID-19 pandemic has been a reminder about how much medicine improves the lives of all humans across the planet; nothing highlights this more than when it is abruptly taken away,” says Dr. Fields.
“It is an example of how prevention of disease is key to social function. I’m making whatever contribution I can to investigate a safe and effective vaccine that could save lives and restore the normal function of our institutions and public well-being.”
The study, funded by The National Institute of Allergy and Infectious Diseases (NIAID), is an open-label trial that will enroll 45 healthy adult volunteers ages 18 to 55.
The vaccine is called mRNA-1273 after a strand of mRNA coding for the spike protein of the SARS-CoV-2 virus.
The Phase 1 clinical trial will administer two vaccinations at 25 mcg, 100 mcg and 250 mcg to subjects in each cohort.
The trial will last 16 months and subjects in the study will be followed for 14 months.
Previously, Dr. Fields worked at the KPWHRI’s Vaccine Treatment Unit in a pandemic preparedness trial for Avian influenza.
Read more on the MSIH website >>
Learn more about BGU’s COVID-19 Response Effort >>
Stories Like This
